BG63327B1 - Липозомен състав, съдържащ селегилин - Google Patents

Липозомен състав, съдържащ селегилин Download PDF

Info

Publication number: BG63327B1
Authority: BG; Bulgaria
Prior art keywords: selegiline; composition; salt; composition according; cyclodextrin
Prior art date: 1994-10-24

Application number

BG101432A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG101432A (bg

Inventor

Michael Mezei

Jozsef Gaal

Gabor Szekacs

Gyula Szebeni

Tamasne Marmarosi

Kalman Magyar

Jozsef Lengyel

Istvan Szatmari

Agnes Tueri

Original Assignee

Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-24

Filing date

1997-04-22

Publication date

2001-10-31

1997-04-22 Application filed by Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. filed Critical Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

1997-12-30 Publication of BG101432A publication Critical patent/BG101432A/xx

2001-10-31 Publication of BG63327B1 publication Critical patent/BG63327B1/bg

Links

239000000203 mixture Substances 0.000 title claims abstract description 77
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims abstract description 37
239000002502 liposome Substances 0.000 claims abstract description 29
229960003946 selegiline Drugs 0.000 claims abstract description 28
150000002632 lipids Chemical class 0.000 claims abstract description 20
238000000034 method Methods 0.000 claims abstract description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
150000003839 salts Chemical class 0.000 claims abstract description 12
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 12
150000003904 phospholipids Chemical class 0.000 claims abstract description 11
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 10
229920000858 Cyclodextrin Polymers 0.000 claims abstract description 9
239000003963 antioxidant agent Substances 0.000 claims abstract description 5
230000003078 antioxidant effect Effects 0.000 claims abstract description 5
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims abstract description 5
239000003755 preservative agent Substances 0.000 claims abstract description 5
208000024827 Alzheimer disease Diseases 0.000 claims abstract description 4
208000003926 Myelitis Diseases 0.000 claims abstract description 4
239000003795 chemical substances by application Substances 0.000 claims abstract description 4
201000003152 motion sickness Diseases 0.000 claims abstract description 4
230000002335 preservative effect Effects 0.000 claims abstract description 4
239000000945 filler Substances 0.000 claims abstract description 3
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
239000002775 capsule Substances 0.000 claims description 11
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
239000004480 active ingredient Substances 0.000 claims description 7
239000003960 organic solvent Substances 0.000 claims description 7
239000000243 solution Substances 0.000 claims description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
229920002125 Sokalan® Polymers 0.000 claims description 4
235000012000 cholesterol Nutrition 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
239000002202 Polyethylene glycol Substances 0.000 claims description 3
208000006011 Stroke Diseases 0.000 claims description 3
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 3
229920001223 polyethylene glycol Polymers 0.000 claims description 3
238000003756 stirring Methods 0.000 claims description 3
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims description 2
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
239000007864 aqueous solution Substances 0.000 claims description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
201000010099 disease Diseases 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
229920000642 polymer Polymers 0.000 claims description 2
229960001295 tocopherol Drugs 0.000 claims description 2
229930003799 tocopherol Natural products 0.000 claims description 2
235000010384 tocopherol Nutrition 0.000 claims description 2
239000011732 tocopherol Substances 0.000 claims description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 1
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 1
229940043377 alpha-cyclodextrin Drugs 0.000 claims 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
229960004853 betadex Drugs 0.000 claims 1
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 1
229940080345 gamma-cyclodextrin Drugs 0.000 claims 1
-1 glycol Chemical compound 0.000 claims 1
239000004034 viscosity adjusting agent Substances 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 14
239000000126 substance Substances 0.000 abstract description 7
208000018737 Parkinson disease Diseases 0.000 abstract description 4
238000007911 parenteral administration Methods 0.000 abstract description 2
230000002490 cerebral effect Effects 0.000 abstract 1
238000007920 subcutaneous administration Methods 0.000 abstract 1
239000013543 active substance Substances 0.000 description 16
210000004369 blood Anatomy 0.000 description 14
239000008280 blood Substances 0.000 description 14
102000010909 Monoamine Oxidase Human genes 0.000 description 13
108010062431 Monoamine oxidase Proteins 0.000 description 13
239000002207 metabolite Substances 0.000 description 12
210000004556 brain Anatomy 0.000 description 11
230000000694 effects Effects 0.000 description 11
210000000056 organ Anatomy 0.000 description 11
238000010521 absorption reaction Methods 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 9
239000002245 particle Substances 0.000 description 8
239000002356 single layer Substances 0.000 description 8
238000009826 distribution Methods 0.000 description 7
210000004185 liver Anatomy 0.000 description 7
241000282887 Suidae Species 0.000 description 6
238000009472 formulation Methods 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
239000011521 glass Substances 0.000 description 5
241000700198 Cavia Species 0.000 description 4
239000011324 bead Substances 0.000 description 4
230000036765 blood level Effects 0.000 description 4
210000002216 heart Anatomy 0.000 description 4
239000010410 layer Substances 0.000 description 4
230000004060 metabolic process Effects 0.000 description 4
229960001252 methamphetamine Drugs 0.000 description 4
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
MEZLKOACVSPNER-UHFFFAOYSA-N selegiline Chemical compound C#CCN(C)C(C)CC1=CC=CC=C1 MEZLKOACVSPNER-UHFFFAOYSA-N 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
241000700199 Cavia porcellus Species 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000009471 action Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
239000010408 film Substances 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
238000011200 topical administration Methods 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000000416 hydrocolloid Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
IYETZZCWLLUHIJ-UHFFFAOYSA-N methyl-(1-phenylpropan-2-yl)-prop-2-ynylazanium;chloride Chemical compound Cl.C#CCN(C)C(C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UHFFFAOYSA-N 0.000 description 2
239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000012047 saturated solution Substances 0.000 description 2
229960003678 selegiline hydrochloride Drugs 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000012360 testing method Methods 0.000 description 2
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
HLLSXSUDPKAYTE-UHFFFAOYSA-N 2-(2-prop-1-ynylphenyl)ethanamine Chemical compound CC#CC1=CC=CC=C1CCN HLLSXSUDPKAYTE-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
101100327819 Caenorhabditis elegans chl-1 gene Proteins 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
UUFAJPMQSFXDFR-LLVKDONJSA-N Norselegiline Chemical compound C#CCN[C@H](C)CC1=CC=CC=C1 UUFAJPMQSFXDFR-LLVKDONJSA-N 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940025084 amphetamine Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
229940088623 biologically active substance Drugs 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Chemical class 0.000 description 1
229920002678 cellulose Chemical class 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000003640 drug residue Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
229940084238 eldepryl Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
239000010985 leather Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000000399 optical microscopy Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
210000003240 portal vein Anatomy 0.000 description 1
230000008569 process Effects 0.000 description 1
239000003368 psychostimulant agent Substances 0.000 description 1
239000000941 radioactive substance Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000010409 thin film Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
229960003732 tyramine Drugs 0.000 description 1
DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000002699 waste material Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
WHGYBXFWUBPSRW-FEYSZYNQSA-N β-dextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)C(O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FEYSZYNQSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Dispersion Chemistry (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Detergent Compositions (AREA)
Manufacturing Of Micro-Capsules (AREA)
Dental Preparations (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BG101432A 1994-10-24 1997-04-22 Липозомен състав, съдържащ селегилин BG63327B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU9403073A HU223475B1 (hu)	1994-10-24	1994-10-24	Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
PCT/HU1995/000052 WO1996012472A1 (en)	1994-10-24	1995-10-20	Liposome composition containing selegilin

Publications (2)

Publication Number	Publication Date
BG101432A BG101432A (bg)	1997-12-30
BG63327B1 true BG63327B1 (bg)	2001-10-31

Family

ID=10985697

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG101432A BG63327B1 (bg)	1994-10-24	1997-04-22	Липозомен състав, съдържащ селегилин

Country Status (30)

Country	Link
US (1)	US5888536A (pt)
EP (1)	EP0788349B1 (pt)
JP (1)	JPH10507749A (pt)
KR (1)	KR100313149B1 (pt)
CN (1)	CN1084186C (pt)
AT (1)	ATE205387T1 (pt)
AU (1)	AU691348B2 (pt)
BG (1)	BG63327B1 (pt)
BR (1)	BR9509517A (pt)
CA (1)	CA2203513C (pt)
CZ (1)	CZ287349B6 (pt)
DE (1)	DE69522701T2 (pt)
DK (1)	DK0788349T3 (pt)
EE (1)	EE03418B1 (pt)
ES (1)	ES2160718T3 (pt)
FI (1)	FI971743A7 (pt)
HU (1)	HU223475B1 (pt)
IL (1)	IL115754A (pt)
NO (1)	NO316354B1 (pt)
NZ (1)	NZ294660A (pt)
PL (1)	PL183104B1 (pt)
PT (1)	PT788349E (pt)
RO (1)	RO116768B1 (pt)
RU (1)	RU2159106C2 (pt)
SK (1)	SK281599B6 (pt)
TW (1)	TW412420B (pt)
UA (1)	UA44289C2 (pt)
WO (1)	WO1996012472A1 (pt)
YU (1)	YU49313B (pt)
ZA (1)	ZA958999B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2319318A1 (en) *	1998-01-27	1999-07-29	Thomas N. Thomas	Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl
DE19814257A1 (de)	1998-03-31	1999-10-07	Asta Medica Ag	Brauseformulierungen
GB9815785D0 (en) *	1998-07-20	1998-09-16	Cerebrus Ltd	Chemical compounds
CN1849112B (zh) *	2003-09-09	2012-06-13	吉里德科学公司	治疗性脂质体
US20080233053A1 (en) *	2005-02-07	2008-09-25	Pharmalight Inc.	Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
CN1813679A (zh) *	2005-11-30	2006-08-09	上海医药(集团)有限公司	一种紫杉烷脂质体冻干组合物及其制备方法
US9445975B2 (en)	2008-10-03	2016-09-20	Access Business Group International, Llc	Composition and method for preparing stable unilamellar liposomal suspension
JP5693026B2 (ja) *	2010-03-12	2015-04-01	株式会社フジモト・コーポレーション	セレギリン含有貼付製剤
JP5623102B2 (ja) *	2010-03-12	2014-11-12	株式会社フジモト・コーポレーション	セレギリン含有貼付製剤
EP2846773A4 (en)	2012-05-10	2015-12-30	Painreform Ltd	DEPOT FORMULATIONS OF A LOCAL ANESTHETICS AND METHOD FOR THE MANUFACTURE THEREOF
WO2016051424A1 (en) *	2014-09-29	2016-04-07	Council Of Scientific & Industrial Research	A formulation useful for delivery of neuro protecting agent
RS65378B1 (sr) *	2017-03-23	2024-04-30	Lipid Systems Sp Z O O	Visokoefikasna inkapsulacija hidrofilnih jedinjenja u unilamelarne lipozome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH588887A5 (pt) *	1974-07-19	1977-06-15	Battelle Memorial Institute
US4485054A (en) *	1982-10-04	1984-11-27	Lipoderm Pharmaceuticals Limited	Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4761288A (en) *	1984-09-24	1988-08-02	Mezei Associates Limited	Multiphase liposomal drug delivery system
GB8807504D0 (en) *	1988-03-29	1988-05-05	Sandoz Ltd	Improvements in/relating to organic compounds
HU208484B (en) *	1988-08-17	1993-11-29	Chinoin Gyogyszer Es Vegyeszet	Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US4937078A (en) *	1988-08-26	1990-06-26	Mezei Associates Limited	Liposomal local anesthetic and analgesic products
CA2039194C (en) *	1990-08-31	1997-01-28	Norton W. Milgram	Uses of l-deprenyl and compositions for same
HU209605B (en) *	1991-04-15	1994-09-28	Chinoin Gyogyszer Es Vegyeszet	Process for production of wather-free transdermal preparation
FR2713087B1 (fr) *	1993-11-30	1996-02-23	Saurat Jean Hilaire	Utilisation de la sélégiline et ses dérivés pour la préparation d'un médicament destiné au traitement du psoriasis.

1994
- 1994-10-24 HU HU9403073A patent/HU223475B1/hu not_active IP Right Cessation
1995
- 1995-10-20 FI FI971743A patent/FI971743A7/fi not_active IP Right Cessation
- 1995-10-20 ES ES95935530T patent/ES2160718T3/es not_active Expired - Lifetime
- 1995-10-20 CZ CZ19971147A patent/CZ287349B6/cs not_active IP Right Cessation
- 1995-10-20 US US08/817,433 patent/US5888536A/en not_active Expired - Fee Related
- 1995-10-20 CA CA002203513A patent/CA2203513C/en not_active Expired - Fee Related
- 1995-10-20 RO RO97-00792A patent/RO116768B1/ro unknown
- 1995-10-20 PT PT95935530T patent/PT788349E/pt unknown
- 1995-10-20 SK SK517-97A patent/SK281599B6/sk unknown
- 1995-10-20 UA UA97052395A patent/UA44289C2/uk unknown
- 1995-10-20 DK DK95935530T patent/DK0788349T3/da active
- 1995-10-20 NZ NZ294660A patent/NZ294660A/en not_active IP Right Cessation
- 1995-10-20 BR BR9509517A patent/BR9509517A/pt not_active IP Right Cessation
- 1995-10-20 EP EP95935530A patent/EP0788349B1/en not_active Expired - Lifetime
- 1995-10-20 KR KR1019970702682A patent/KR100313149B1/ko not_active Expired - Fee Related
- 1995-10-20 CN CN95195853A patent/CN1084186C/zh not_active Expired - Fee Related
- 1995-10-20 DE DE69522701T patent/DE69522701T2/de not_active Expired - Fee Related
- 1995-10-20 AT AT95935530T patent/ATE205387T1/de not_active IP Right Cessation
- 1995-10-20 RU RU97108051/14A patent/RU2159106C2/ru not_active IP Right Cessation
- 1995-10-20 EE EE9700102A patent/EE03418B1/xx not_active IP Right Cessation
- 1995-10-20 PL PL95319875A patent/PL183104B1/pl not_active IP Right Cessation
- 1995-10-20 AU AU37518/95A patent/AU691348B2/en not_active Ceased
- 1995-10-20 WO PCT/HU1995/000052 patent/WO1996012472A1/en not_active Ceased
- 1995-10-20 JP JP8513742A patent/JPH10507749A/ja active Pending
- 1995-10-24 TW TW084111224A patent/TW412420B/zh not_active IP Right Cessation
- 1995-10-24 IL IL11575495A patent/IL115754A/xx not_active IP Right Cessation
- 1995-10-24 ZA ZA958999A patent/ZA958999B/xx unknown
- 1995-10-25 YU YU67195A patent/YU49313B/sh unknown
1997
- 1997-04-22 BG BG101432A patent/BG63327B1/bg unknown
- 1997-04-23 NO NO19971870A patent/NO316354B1/no unknown

Also Published As

Publication number	Publication date
NZ294660A (en)	1998-05-27
SK51797A3 (en)	1997-11-05
PT788349E (pt)	2001-12-28
YU49313B (sh)	2005-06-10
KR100313149B1 (ko)	2002-02-19
NO971870D0 (no)	1997-04-23
HU9403073D0 (en)	1994-12-28
MX9703019A (es)	1997-10-31
EP0788349B1 (en)	2001-09-12
DK0788349T3 (da)	2001-11-26
IL115754A (en)	1999-07-14
NO316354B1 (no)	2004-01-19
AU3751895A (en)	1996-05-15
FI971743L (fi)	1997-04-23
BR9509517A (pt)	1997-12-30
CN1163563A (zh)	1997-10-29
IL115754A0 (en)	1996-01-19
FI971743A0 (fi)	1997-04-23
HUT76053A (en)	1997-06-30
BG101432A (bg)	1997-12-30
JPH10507749A (ja)	1998-07-28
TW412420B (en)	2000-11-21
SK281599B6 (sk)	2001-05-10
ES2160718T3 (es)	2001-11-16
KR970706797A (ko)	1997-12-01
RU2159106C2 (ru)	2000-11-20
CZ114797A3 (en)	1997-10-15
RO116768B1 (ro)	2001-06-29
CA2203513A1 (en)	1996-05-02
ATE205387T1 (de)	2001-09-15
DE69522701D1 (de)	2001-10-18
US5888536A (en)	1999-03-30
CA2203513C (en)	2001-10-09
CZ287349B6 (en)	2000-10-11
EE03418B1 (et)	2001-06-15
UA44289C2 (uk)	2002-02-15
YU67195A (sh)	1998-07-10
PL183104B1 (pl)	2002-05-31
PL319875A1 (en)	1997-09-01
WO1996012472A1 (en)	1996-05-02
CN1084186C (zh)	2002-05-08
ZA958999B (en)	1996-05-15
NO971870L (no)	1997-06-24
FI971743A7 (fi)	1997-04-23
HU223475B1 (hu)	2004-07-28
EE9700102A (et)	1997-10-15
DE69522701T2 (de)	2002-07-11
AU691348B2 (en)	1998-05-14
EP0788349A1 (en)	1997-08-13

Publication	Publication Date	Title
KR970005171B1 (ko)	1997-04-14	아라키돈산 대사물질 관련 리포좀 제조방법 및 그 제제
CN102159202A (zh)	2011-08-17	施用局部抗真菌制剂治疗真菌感染的方法
JP4885715B2 (ja)	2012-02-29	イリノテカン製剤
EP1105098A1 (en)	2001-06-13	Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
JP2001510451A (ja)	2001-07-31	弱塩基性薬物を担持するイオン運搬体―中介リポゾーム
BG63327B1 (bg)	2001-10-31	Липозомен състав, съдържащ селегилин
US5364631A (en)	1994-11-15	Tocopherol-based pharmaceutical systems
EP0382779B1 (en)	1993-08-11	Tocopherol-based pharmaceutical systems
JP2003516348A (ja)	2003-05-13	がん治療のための細胞増殖抑制剤及び電子受容体を含有する医薬製剤
US20080193509A1 (en)	2008-08-14	Liposome Preparation Containing Slightly Water-Soluble Camptothecin
JP4931369B2 (ja)	2012-05-16	リポソームおよびそれを含む処置用の組成物
EP2231190A1 (en)	2010-09-29	Particulate drug carriers as desensitizing agents
US6013278A (en)	2000-01-11	Liposomal antineoplaston therapies with markedly improved antineoplastic activity
US20090196914A1 (en)	2009-08-06	Liposomal l-carnitine
WO1991006310A1 (en)	1991-05-16	Liposomal compositions
MXPA97003019A (en)	1998-07-03	Liposoma composition containing selegil
JPH11171772A (ja)	1999-06-29	抗腫瘍薬のリポソーム化製剤